MDT

88.62

+1.08%↑

VEEV

280.06

-0.3%↓

A

121.12

+1.59%↑

WBA

11.52

0%↓

HQY

103.04

+1.28%↑

MDT

88.62

+1.08%↑

VEEV

280.06

-0.3%↓

A

121.12

+1.59%↑

WBA

11.52

0%↓

HQY

103.04

+1.28%↑

MDT

88.62

+1.08%↑

VEEV

280.06

-0.3%↓

A

121.12

+1.59%↑

WBA

11.52

0%↓

HQY

103.04

+1.28%↑

MDT

88.62

+1.08%↑

VEEV

280.06

-0.3%↓

A

121.12

+1.59%↑

WBA

11.52

0%↓

HQY

103.04

+1.28%↑

MDT

88.62

+1.08%↑

VEEV

280.06

-0.3%↓

A

121.12

+1.59%↑

WBA

11.52

0%↓

HQY

103.04

+1.28%↑

Search

Krystal Biotech Inc

Gesloten

SectorGezondheidszorg

143.13 2.56

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

137.61

Max

143.32

Belangrijke statistieken

By Trading Economics

Inkomsten

-9.7M

36M

Verkoop

-3M

88M

K/W

Sectorgemiddelde

33.591

39.564

Winstmarge

40.521

Werknemers

275

EBITDA

-5.1M

38M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+39.82% upside

Dividenden

By Dow Jones

Volgende Winsten

4 aug 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-763M

4B

Vorige openingsprijs

140.57

Vorige sluitingsprijs

143.13

Nieuwssentiment

By Acuity

50%

50%

162 / 376 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

Krystal Biotech Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

8 jul 2025, 19:37 UTC

Belangrijke Marktbewegers
Acquisities, Fusies, Overnames

M3-Brigade Shares Fall on Merger With ReserveOne

8 jul 2025, 23:45 UTC

Marktinformatie

Gold Edges Lower, Weighed by Higher Treasury Yields -- Market Talk

8 jul 2025, 23:42 UTC

Marktinformatie

Nikkei May Rise as Yen Weakens -- Market Talk

8 jul 2025, 23:27 UTC

Marktinformatie

Australian REITs Yet to Offer Enough Appeal -- Market Talk

8 jul 2025, 23:27 UTC

Marktinformatie

Global Equities Roundup: Market Talk

8 jul 2025, 23:21 UTC

Marktinformatie

Summerset Bull Lauds Strong 2Q Sales Volumes -- Market Talk

8 jul 2025, 23:21 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

8 jul 2025, 22:29 UTC

Acquisities, Fusies, Overnames

Capricorn to Pay A$1.5 Million in Cash and Shares

8 jul 2025, 22:28 UTC

Acquisities, Fusies, Overnames

Capricorn Metals Enters Binding Agreement to Buy Claw Gold Project

8 jul 2025, 21:58 UTC

Marktinformatie

Kura Sushi Closely Watching U.S. Tariff Negotiations on Asian Goods -- Market Talk

8 jul 2025, 20:50 UTC

Marktinformatie

Financial Services Roundup: Market Talk

8 jul 2025, 20:50 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

8 jul 2025, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

8 jul 2025, 20:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

8 jul 2025, 19:53 UTC

Marktinformatie

Copper Posts Biggest One-Day Gain Ever to Hit Record on Tariff Chatter -- Market Talk

8 jul 2025, 19:53 UTC

Marktinformatie

Market Talk Roundup: Latest on U.S. Politics

8 jul 2025, 19:45 UTC

Marktinformatie

Canada Unlikely to Succeed in Bid for Tariff-Free Trade With U.S. -- Market Talk

8 jul 2025, 19:29 UTC

Marktinformatie

U.S. Consumer-Credit Growth Slowed in May -- Market Talk

8 jul 2025, 19:20 UTC

Marktinformatie

U.S. Natural Gas Futures Settle Lower -- Market Talk

8 jul 2025, 19:11 UTC

Marktinformatie

Bank of Canada's Rate Cuts Deliver Muted Relief Along the Curve -- Market Talk

8 jul 2025, 19:01 UTC

Marktinformatie

Oil Futures Gain With Support From Products -- Market Talk

8 jul 2025, 18:49 UTC

Winsten

Hershey Names New CEO, Continuing Leadership Shuffle. The Stock Falls. -- Barrons.com

8 jul 2025, 18:41 UTC

Marktinformatie

Mexico's Inflation Seen Mixed in June -- Market Talk

8 jul 2025, 18:38 UTC

Marktinformatie

Gold Falls as Markets Digest Details of Trump Tariffs -- Market Talk

8 jul 2025, 18:23 UTC

Marktinformatie

Analysts Anticipate Lower Ethanol Inventories -- Market Talk

8 jul 2025, 18:10 UTC

Marktinformatie

Market Talk Roundup: Latest on U.S. Politics

8 jul 2025, 18:10 UTC

Marktinformatie

Freeport-McMoRan Jumps on Trump Tariff Plan for Copper Imports -- Market Talk

8 jul 2025, 17:24 UTC

Marktinformatie

Election, Dollar Seen as Potential Headwinds for Ibovespa -- Market Talk

8 jul 2025, 17:06 UTC

Marktinformatie

KeyCorp and Regional Banks Set for a Catchup -- Market Talk

8 jul 2025, 16:20 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

Peer Vergelijking

Prijswijziging

Krystal Biotech Inc Prognose

Koersdoel

By TipRanks

39.82% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 195.38 USD  39.82%

Hoogste 240 USD

Laagste 155 USD

Gebaseerd op 9 Wall Street-analisten die 12-maands prijsdoelen bieden voor Krystal Biotech Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

9 ratings

8

Buy

1

Hold

0

Sell

Technische score

By Trading Central

133.221 / 169.73Steun & Weerstand

Korte Termijn

Very Strong Bearish Evidence

Gemiddeld Termijn

Strong Bearish Evidence

Lange Termijn

Bearish Evidence

Sentiment

By Acuity

162 / 376 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Krystal Biotech Inc

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.